IN Insider Trading (InMed Pharmaceuticals)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$42,345.03
Insider Selling (Last 12 Months): C$0.00
InMed Pharmaceuticals Share Price & Price History
Current Price: C$0.00
Price Change: +0.30 (1.20%)
As of 05/7/2021 01:00 AM ET
The Incredible Dividend Map... Where Stocks Yield 26% a Year!
From Investing Daily | Ad
What’s the highest-yielding stock you’ve ever owned?
The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
InMed Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/13/2022 | Eric Ashley Adams | Director | Buy | 8,560 | C$1.07 | C$9,167.76 | 44,843 | |
| 1/24/2022 | Bruce Colwill | Senior Officer | Buy | 5,000 | C$1.36 | C$6,798.13 | 11,515 | |
| 9/28/2021 | Eric Ashley Adams | Director | Buy | 11,400 | C$2.31 | C$26,379.14 | 27,483 | |
| 11/28/2019 | Eric Ashley Adams | Director | Buy | 100,000 | C$0.25 | C$25,000.00 | 530,725 | |
| 10/31/2019 | Alexandra Diane Janet Mancini | Senior Officer | Buy | 8,500 | C$0.25 | C$2,097.80 | 166,500 | |
| 10/28/2019 | Alexandra Diane Janet Mancini | Senior Officer | Buy | 10,000 | C$0.26 | C$2,600.00 | 158,000 | |
| 10/24/2019 | Alexandra Diane Janet Mancini | Senior Officer | Buy | 1,500 | C$0.26 | C$390.00 | 148,000 | |
| 10/21/2019 | Alexandra Diane Janet Mancini | Senior Officer | Buy | 2,500 | C$0.27 | C$675.00 | 136,500 | |
| 10/17/2019 | Alexandra Diane Janet Mancini | Senior Officer | Buy | 14,000 | C$0.27 | C$3,710.00 | 134,000 | |
| 10/15/2019 | Alexandra Diane Janet Mancini | Senior Officer | Buy | 10,000 | C$0.28 | C$2,800.00 | 110,000 | |
| 10/11/2019 | Alexandra Diane Janet Mancini | Senior Officer | Buy | 15,000 | C$0.26 | C$3,825.00 | 100,000 | |
High Arch Potential Stock
From Wealthy Millionaire | Ad
If you're looking for a hot new sector, watch this stock closely.
Click for ticker & full details
SEC Filings (Institutional Ownership Changes) for InMed Pharmaceuticals (TSE:IN)
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Read More on InMed Pharmaceuticals
Today's Range
Now: N/A
52 Week Range
Now: N/A
Volume
17,035 shs
Average Volume
29,552 shs
Market Capitalization
C$33.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of InMed Pharmaceuticals?
